Description

Rhythm Pharmaceuticals’ Big Break: How HO Approval Could Unlock IMCIVREE’s Next Market!

Rhythm Pharmaceuticals reported its first quarter 2026 financial results, reflecting continued advancement across its franchise and geographic markets, particularly with its flagship therapy IMCIVREE. Global net revenues reached $60.1 million, a 5% sequential increase from the prior quarter, supported by growth in both the United States—constituting 61% of revenues—and international regions. Growth outside the U.S. was notably strong at 27% sequentially, driven by increased sales volumes in Germany, France, Saudi Arabia, and Greece. The patient base on reimbursed therapy grew 8% globally, with Bardet-Biedl syndrome (BBS) remaining a steady contributor and early access programs in France and Italy supporting hypothalamic obesity (HO) therapy uptake internationally. The company highlighted its recent approval and launch of IMCIVREE for acquired hypothalamic obesity (HO), expanding the addressable market beyond ultra-rare BBS. Estimated patient populations include approximately 10,000 in the U.S.